002589.SZ SHZ
Realcan Pharmaceutical Group Co., Ltd.
1W: -8.9%
1M: +2.8%
3M: +26.2%
YTD: -2.7%
1Y: +5.5%
3Y: -2.7%
5Y: -26.0%
¥3.27 ($0.49)
+0.03 (+0.93%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$16.0B
-4.2% ▼
5Y CAGR: -13.2%
Total Liabilities
$10.3B
-6.8% ▼
5Y CAGR: -14.2%
Shareholders Equity
$5.5B
+1.7% ▲
5Y CAGR: -5.1%
Cash & Investments
$5.0B
-1.5% ▼
5Y CAGR: -0.2%
Total Debt
$6.4B
-5.9% ▼
5Y CAGR: -0.5%
Net Debt
$1.4B
-18.1% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $5.7B | $4.6B | $5.3B | $5.1B | $5.0B |
| Short-Term Investments | $41M | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $5.8B | $4.6B | $5.3B | $5.1B | $5.0B |
| Net Receivables | $15.2B | $11.3B | $6.3B | $5.2B | $5.3B |
| Inventory | $2.9B | $2.1B | $955M | $1.1B | $735M |
| Other Current Assets | $2.6B | $2.7B | $59M | $50M | $47M |
| Total Current Assets | $26.5B | $20.7B | $12.8B | $11.5B | $11.1B |
| Property, Plant & Equip. | $2.7B | $2.5B | $2.3B | $2.3B | $2.2B |
| Goodwill & Intangibles | $1.0B | $1.1B | $771M | $699M | $588M |
| Long-Term Investments | $737M | $1.6B | $1.7B | $852M | $747M |
| Other Non-Current Assets | $264M | $391M | $650M | $1.1B | $1.1B |
| Total Non-Current Assets | $4.8B | $5.7B | $5.5B | $5.2B | $4.9B |
| Total Assets | $31.3B | $26.4B | $18.3B | $16.7B | $16.0B |
| — Liabilities — | |||||
| Accounts Payable | $8.3B | $9.8B | $7.7B | $3.7B | $3.4B |
| Short-Term Debt | $10.1B | $4.2B | $3.8B | $6.6B | $6.1B |
| Deferred Revenue | $0 | $2.2B | $32M | $0 | $0 |
| Other Current Liabilities | $2.1B | $314M | $881M | $133M | $222M |
| Total Current Liabilities | $21.2B | $16.5B | $12.5B | $10.8B | $9.9B |
| Long-Term Debt | $8M | $48M | $67M | $261M | $327M |
| Other Non-Current Liab. | $246M | $7M | $2M | $2M | $0 |
| Total Non-Current Liabilities | $470M | $196M | $111M | $311M | $384M |
| Total Liabilities | $21.6B | $16.7B | $12.6B | $11.1B | $10.3B |
| — Equity — | |||||
| Common Stock | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B |
| Retained Earnings | $2.0B | $2.1B | $280M | $294M | $277M |
| Accumulated OCI | $213M | $231M | $231M | $257M | $0 |
| Total Stockholders Equity | $7.5B | $7.6B | $5.4B | $5.4B | $5.5B |
| Total Liabilities & Equity | $31.3B | $26.4B | $18.3B | $16.7B | $16.0B |
| — Key Metrics — | |||||
| Total Debt | $10.1B | $4.3B | $3.9B | $6.8B | $6.4B |
| Net Debt | $3.8B | -$310M | -$1.4B | $1.8B | $1.4B |
| Total Investments | $778M | $1.6B | $1.7B | $852M | $747M |